Immature granulocytes as a biomarker for diabetic retinopathy progression without anti-VEGF therapy: A cross sectional study

被引:0
|
作者
Bayram, Ergul [1 ]
Zor, Ramazan Kursad [2 ]
Ayan, Durmus [1 ,3 ]
机构
[1] Nigde Omer Halisdemir Univ, Res & Training Hosp, Med Biochem, Nigde, Turkiye
[2] Nigde Omer Halisdemir Univ, Fac Med, Ophthalmol, Nigde, Turkiye
[3] Nigde Omer Halisdemir Univ, Fac Med, Med Biochem, Nigde, Turkiye
关键词
Diabetic retinopathy; Immature granulocyte count; Immature granulocyte percentage; Inflammation; Delta neutrophil index; DELTA NEUTROPHIL INDEX; IMMUNE-INFLAMMATION INDEX; TO-LYMPHOCYTE RATIO; PROGNOSTIC MARKER; RESPONSE INDEX; COUNT; INFECTION;
D O I
10.1007/s13410-025-01484-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diabetic retinopathy (DR) is one of the most common complications of diabetes and is the leading cause of low vision and blindness worldwide. Objective The present study aimed to evaluate delta neutrophil index (DNI), the immature granulocyte count (IG#), and percentage (IG%) in the diabetic group without retinopathy and in the diabetic group with DR. Methods A total of 175 participants were diagnosed with diabetes mellitus (DM (non-DR), 128 patients were diagnosed with nonproliferative diabetic retinopathy (NPDR) (n = 89), and one was diagnosed with diabetic proliferative retinopathy (PDR) (n = 39). Results The level of GR# and GR% in PDR was statistically significant than non-DR and NPDR (P = 0.03 and p = 0.02, respectively). The sensitivity and specificity of GR# and GR% for predicting progression from NPDR to PDR were determined to be 66.7% and 44.9%, respectively (area under curve [AUC] = 0.621, p = 0.029; 95% confidence interval [CI] = 0.512-0.730; and area under curve [AUC] = 0.623, p = 0.027, 95% confidence interval [CI] = 0.517-0.728). Additionally, IG# was not an independent risk factor for DR (p > 0.05). There were no significant differences in DNI among the NDR, NPDR, and PDR groups (p > 0.05). Conclusion IG# and IG% may be promising minimally invasive biomarkers for distinguishing NPDR from PDR but not DNI. We believe that they are markers that need to be confirmed in prospective studies for obtaining more reliable results in the detection of DR.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy
    Bolinger, Mark T.
    Antonetti, David A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (09)
  • [22] Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy: a cross-sectional study
    Banaee, Touka
    Kakhki, Ramin Daneshvar
    Abrishami, Mojtaba
    Mahmoudi, Mahmoud
    Farzadnia, Mehdi
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 (02) : 168 - 174
  • [23] Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review
    Jason A. Zehden
    Xavier M. Mortensen
    Ashvini Reddy
    Alice Yang Zhang
    Current Diabetes Reports, 2022, 22 : 525 - 536
  • [24] Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review
    Zehden, Jason A.
    Mortensen, Xavier M.
    Reddy, Ashvini
    Zhang, Alice Yang
    CURRENT DIABETES REPORTS, 2022, 22 (10) : 525 - 536
  • [25] Modulation of Fibrosis and Neovascularization by Bevacizumab Anti-VEGF Blockade in Proliferative Diabetic Retinopathy
    Ianopol, N.
    Kirchhof, B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [26] Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview
    Khandelwal, Aman
    Gowthamarajan, K.
    Nirmal, Jayabalan
    Ponnusankar, S.
    CURRENT DIABETES REVIEWS, 2025, 21 (09)
  • [27] Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy
    R. Simó
    C. Hernández
    Diabetologia, 2008, 51
  • [28] Intravitreous anti-VEGF for diabetic retinopathy:: hopes and fears for a new therapeutic strategy
    Simo, R.
    Hernandez, C.
    DIABETOLOGIA, 2008, 51 (09) : 1574 - 1580
  • [29] Epiretinal Membrane Is Associated with Diabetic Retinopathy Severity and Cumulative Anti-VEGF Injections
    Kakihara, Shinji
    Abdelsalam, Mohamed
    Zhuang, Kallista
    Fawzi, Amani A.
    OPHTHALMOLOGY SCIENCE, 2025, 5 (03):
  • [30] Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema
    Imazeki, Makoto
    Noma, Hidetaka
    Yasuda, Kanako
    Motohashi, Ryosuke
    Goto, Hiroshi
    Shimura, Masahiko
    OPHTHALMIC RESEARCH, 2021, 64 (01) : 43 - 49